New York, Oct 5: Children with congenital heart disease and attention deficit hyperactivity disorder (ADHD) can take stimulant medications without fear of significant cardiovascular side effects, claims a study. (Read: US approves breakthrough drug to fight lung cancer) Also Read - Of Parenting, Sweet Lies & Much More ...
“Children with congenital heart disease are at high risk for ADHD, but fears about cardiovascular side effects, including sudden death, limit the use of stimulant medications,” said senior author of the study Julia Anixt, developmental and behavioural pediatrician at Cincinnati Children’s Hospital Medical Centre in the US. Also Read - Viral Video: Man Gets Married For The 37th Time In Front of His 28 Wives, 35 Children & 126 Grandkids | Watch
“This study indicates that stimulants are both effective and safe when prescribed with appropriate monitoring and in collaboration with the patient’s cardiologist,” Anixt noted. The researchers studied 44 children between the ages of six and 18 seen in the Cincinnati Children’s Heart Institute Kindervelt Neurodevelopmental and Educational Clinic. Also Read - Ivermectin To Plasma Therapy, Things That Are NOT Used in COVID Treatment Anymore
They compared these patients to those with similar heart disease but who were not treated with stimulants. The researchers found that stimulant medications pose no increased risk for death or changes in cardiac vital signs, such as blood pressure or heart rate, even for children with ADHD and severe heart conditions.
They also found that when treated with stimulant medications, patients had significant improvements in ADHD symptoms as measured by standardised rating scales. Since 2006, the US Food and Drug Administration has required labelling of stimulant medications to include a warning that they generally should not be used in children and adolescents with serious structural cardiac abnormalities, cardiomyopathy or arrhythmias.
However, stimulants are the most effective medication to treat ADHD symptoms, and patient families, cardiologists, and developmental pediatricians must together weigh the risks and benefits of medication treatment options for each individual patient, Anixt noted. The study was presented at the annual meeting of the Society for Developmental and Behavioural Pediatrics in Las Vegas, US.